Andrew von Eschenbach, Lester Crawford, Douglas Throckmorton, Walter Narajowski, Gustavo Salem | GenomeWeb

Andrew von Eschenbach has been named acting commissioner of the US Food and Drug Administration following the resignation of former commissioner Lester Crawford last week.

Von Eschenbach has been director of the National Cancer Institute, part of the National Institutes of Health, since January 2002. Before that, he worked as a doctor and executive at the M D Anderson Cancer Center in Houston. Von Eschenbach has said that he intends to act as both head of the FDA and director of NCI.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.